In our study, the lack of favorable prognostic value of the NPM1 mutated/FLT3–ITD negative genotype in CN-AML patients treated with GO can be at least partially explained by the fact that FLT3–ITD mutations confer a higher sensitivity to GO (see below), which is likely to compensate the benefit of being FLT3–ITD negative. This evidence concerns the gene FLT3 and acute myeloid leukemia.